AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32527167 — intervention group
Group type: COMPARATOR
Intervention: Stripping technique (laparoscopic decapsulation)
Number of subjects: 16
Study 35888587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation combined with point-light display observation (2 times per day for 5 min, 3 days a week)
Number of subjects: 0
Study 35888587 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment (2 sessions per day for 90 min, 5 days a week)
Number of subjects: 0
Study 34314392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 144
Study 34314392 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 144
Study 35963072 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week integrated childbirth education program including simulation-based learning and mindfulness techniques (n = 53)
Number of subjects: 106
Study 35963072 — intervention group
Group type: COMPARATOR
Intervention: Usual standard prenatal care (n = 53)
Number of subjects: 106
Study 32702190 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with progression-free survival as primary endpoint
Number of subjects: 0
Study 32702190 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with response rate as primary endpoint
Number of subjects: 0
Study 32702190 — intervention group
Group type: COMPARATOR
Intervention: Studies for non-lead indication
Number of subjects: 0
Study 32702190 — intervention group
Group type: COMPARATOR
Intervention: Studies for first-line therapy
Number of subjects: 0
Study 32702190 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies without strong prior evidence listed
Number of subjects: 0
Study 34341905 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK-fusion positive MDACC patients
Number of subjects: 199
Study 34341905 — intervention group
Group type: COMPARATOR
Intervention: NTRK-fusion negative TCGA patients
Number of subjects: 199
Study 34452979 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of normal fidgety movements (FMs)
Number of subjects: 118
Study 34452979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motor optimality score-revised (MOS-R)
Number of subjects: 118
Study 35410967 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (15 mg/m2 daily for 6 days)
Number of subjects: 365
Study 35410967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 32147337 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 18
Study 32147337 — intervention group
Group type: COMPARATOR
Intervention: Cortical suture button fixation
Number of subjects: 18
Study 34665573 — intervention group
Group type: EXPERIMENTAL
Intervention: CFHealthHub intervention (nebuliser with electronic monitoring, data transfer to digital platform, adherence monitoring via app, support from trained interventionist)
Number of subjects: 608
Study 34665573 — intervention group
Group type: EXPERIMENTAL
Intervention: CFHealthHub intervention
Number of subjects: 608
Study 34665573 — intervention group
Group type: COMPARATOR
Intervention: Usual care (clinic visits every 3 months)
Number of subjects: 608
Study 34665573 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic modelling of CFHealthHub intervention
Number of subjects: 608
Study 33590829 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg QD)
Number of subjects: 0
Study 33590829 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg EOW)
Number of subjects: 0
Study 33590829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33590829 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib vs Adalimumab
Number of subjects: 0
Study 33590829 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0
Study 33371023 — intervention group
Group type: EXPERIMENTAL
Intervention: Physitrack online exercise prescription tool
Number of subjects: 54
Study 33371023 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-based methods
Number of subjects: 54
Study 33371023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Physitrack and paper-based)
Number of subjects: 54
Study 35101942 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monotherapy (first-line and second-line)
Number of subjects: 0
Study 33798819 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning convolution neural network (DL-CNN) system for differentiating NMIBC and MIBC on contrast-enhanced CT images.
Number of subjects: 369
Study 33798819 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithms with pretrained bases from ImageNet dataset.
Number of subjects: 369
Study 32546251 — intervention group
Group type: EXPERIMENTAL
Intervention: Reh@City v2.0 (adaptive cognitive training through everyday tasks VR simulations)
Number of subjects: 36
Study 32546251 — intervention group
Group type: COMPARATOR
Intervention: Task Generator (TG: content equivalent and adaptive paper-and-pencil training)
Number of subjects: 36
Study 32546251 — intervention group
Group type: EXPERIMENTAL
Intervention: Reh@City v2.0
Number of subjects: 36
Study 33768775 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric isokinetic training
Number of subjects: 63
Study 33768775 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric isokinetic training
Number of subjects: 63
Study 33768775 — intervention group
Group type: COMPARATOR
Intervention: Resistance bands training
Number of subjects: 63
Study 33308423 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 testing (self-swabs)
Number of subjects: 280327
Study 33308423 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group (17-24 years)
Number of subjects: 280327
Study 33308423 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors (patient-facing role, working outside home)
Number of subjects: 280327
Study 33308423 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom reporting
Number of subjects: 280327
Study 33409669 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher educational attainment
Number of subjects: 655666
Study 33409669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 655666
Study 33409669 — intervention group
Group type: EXPERIMENTAL
Intervention: More years of education
Number of subjects: 655666
Study 33409669 — intervention group
Group type: COMPARATOR
Intervention: Cognitive performance (after controlling for educational attainment)
Number of subjects: 655666
Study 35526026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanreqing oral liquid, 20 mL three times daily for seven consecutive days
Number of subjects: 270
Study 35526026 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral liquid, 20 mL three times daily for seven consecutive days
Number of subjects: 270
Study 34891146 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio labeling of images
Number of subjects: 11
Study 34891146 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual labeling of images
Number of subjects: 11
Study 33203708 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 2500
Study 33203708 — intervention group
Group type: COMPARATOR
Intervention: Passive surveillance
Number of subjects: 2500
Study 35276914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis strain Plasma (LC‐Plasma) administered as a beverage (1.0 × 10^11 count LC‐Plasma/day/person)
Number of subjects: 0
Study 35276914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis strain Plasma (LC‐Plasma)
Number of subjects: 0
Study 33522066 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound-guided puncture-aspiration (TUGPA)
Number of subjects: 150
Study 33522066 — intervention group
Group type: COMPARATOR
Intervention: Traditional conservative surgery (CS)
Number of subjects: 150
Study 33101559 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light therapy with electromagnetic field (MLT)
Number of subjects: 60
Study 33101559 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (CT)
Number of subjects: 60
Study 36293616 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic diet (VLCKD)
Number of subjects: 268
Study 36293616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 268
Study 34425585 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute application of 4% hydrogen peroxide
Number of subjects: 92
Study 34425585 — intervention group
Group type: COMPARATOR
Intervention: 120-minute application of 4% hydrogen peroxide
Number of subjects: 92
Study 34425585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study 33689656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus contact lens (MiSight)
Number of subjects: 28
Study 33689656 — intervention group
Group type: COMPARATOR
Intervention: Monofocal contact lens (Proclear 1-day)
Number of subjects: 28
Study 33689656 — intervention group
Group type: COMPARATOR
Intervention: Baseline (naked eye condition)
Number of subjects: 28
Study 34500022 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐SCA patients
Number of subjects: 6849
Study 34500022 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐SCA patients after ICD implantation
Number of subjects: 6849
Study 34500022 — intervention group
Group type: COMPARATOR
Intervention: MI‐SCA patients without ICD implantation
Number of subjects: 6849
Study 34982369 — intervention group
Group type: EXPERIMENTAL
Intervention: TT (TACE)
Number of subjects: 84
Study 34982369 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TT (TACE + Sora)
Number of subjects: 84
Study 34982369 — intervention group
Group type: COMPARATOR
Intervention: Non-TT (TACE)
Number of subjects: 84
Study 33612629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Education (NE)
Number of subjects: 121
Study 33612629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Nutrient Biscuit (MNB)
Number of subjects: 121
Study 33612629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nutrition Education and Multi-Nutrient Biscuits (NE+MNB)
Number of subjects: 121
Study 33612629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 33592624 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Interventions (BAIs) including Motivational Interviewing with Personalized Feedback (MI + PF), Group Motivational Interviewing (GMI), and stand-alone Personalized Feedback (PF)
Number of subjects: 6801
Study 33592624 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6801
Study 33023221 — intervention group
Group type: COMPARATOR
Intervention: Low Protein (LP) - 15 g protein
Number of subjects: 26
Study 33023221 — intervention group
Group type: COMPARATOR
Intervention: Medium Protein (MP) - 30 g protein
Number of subjects: 26
Study 33023221 — intervention group
Group type: COMPARATOR
Intervention: High Protein (HP) - 45 g protein
Number of subjects: 26
Study 33023221 — intervention group
Group type: COMPARATOR
Intervention: Control - 7 g protein
Number of subjects: 26
Study 33023221 — intervention group
Group type: COMPARATOR
Intervention: Control (experiment 2)
Number of subjects: 26
Study 33023221 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) (experiment 2)
Number of subjects: 26
Study 35988911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 35988911 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Exercise (PLA + EX)
Number of subjects: 10
Study 35988911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein (PRO)
Number of subjects: 10
Study 35988911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + Exercise (PRO + EX)
Number of subjects: 10
Study 35988911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Number of subjects: 10
Study 35988911 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 33615957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with cTACE + MWA (Group 3)
Number of subjects: 265
Study 33615957 — intervention group
Group type: COMPARATOR
Intervention: TACE (Group 1)
Number of subjects: 265
Study 33615957 — intervention group
Group type: COMPARATOR
Intervention: MWA (Group 2)
Number of subjects: 265
Study 33794965 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito Magnet
Number of subjects: 0
Study 33794965 — intervention group
Group type: COMPARATOR
Intervention: Human Landing Catch (HLC)
Number of subjects: 0
Study 33794965 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Baited Trap (HBT)
Number of subjects: 0
Study 33794965 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC Light Trap
Number of subjects: 0
Study 33371155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 360
Study 33371155 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group (NAG)
Number of subjects: 360
Study 33371155 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (WLG)
Number of subjects: 360
Study 35865817 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical intravenous antibiotic therapy during endotherapy (Group 1)
Number of subjects: 62
Study 35865817 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy during endoscopic drainage (Group 2)
Number of subjects: 62
Study 33600025 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary vein isolation (PVI) ablation
Number of subjects: 900
Study 33600025 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + fibrosis-guided ablation
Number of subjects: 900
Study 32068463 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted cycling during hemodialysis (condition 1)
Number of subjects: 10
Study 32068463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with blood flow restriction while off hemodialysis (condition 2)
Number of subjects: 10
Study 32068463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling with blood flow restriction during hemodialysis (condition 3)
Number of subjects: 10
Study 32068463 — intervention group
Group type: COMPARATOR
Intervention: Blood flow restriction during aerobic exercise
Number of subjects: 10
Study 35585484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of individualized assessment, transition navigator, virtual patient skills-building, and virtual structured education program.
Number of subjects: 0
Study 35585484 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care defined by each participating center (Control group).
Number of subjects: 0
Study 35578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration with a target of 2–2.5 times baseline aPTT
Number of subjects: 0
Study 35578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration with a target of 1.5–2 times baseline aPTT
Number of subjects: 0
Study 35578271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin guided by weight and renal function
Number of subjects: 0
Study 32977015 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 124
Study 32977015 — intervention group
Group type: COMPARATOR
Intervention: Conventional priming
Number of subjects: 124
Study 36314123 — intervention group
Group type: EXPERIMENTAL
Intervention: TASC (Telehealth After Stroke Care)
Number of subjects: 50
Study 36314123 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 33259725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Counseling (TC)
Number of subjects: 0
Study 33259725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study 33096193 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper NEXT (PTN)
Number of subjects: 24
Study 33096193 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Gold (PTG)
Number of subjects: 24
Study 33096193 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 24
Study 35922107 — intervention group
Group type: EXPERIMENTAL
Intervention: Suchana intervention
Number of subjects: 0
Study 35922107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33247085 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 12019
Study 33247085 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 12019
Study 33831327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (200 micrograms, orally administered, 4 times daily for 8 weeks)
Number of subjects: 36
Study 33831327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33831327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 36
Study 32600942 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-only strategy
Number of subjects: 5155
Study 32600942 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 5155
Study 34924224 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery (four sessions over four consecutive days using headphones)
Number of subjects: 70
Study 34924224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guided imagery)
Number of subjects: 70
Study 33559019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 44
Study 33559019 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 44
Study 32094516 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-FES rowing (n=10), 6 months, 3 times per week, 70-85% of maximal heart rate
Number of subjects: 25
Study 32094516 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n=15), either arm ergometer exercise (n=6) or waitlist (n=9)
Number of subjects: 25
Study 34695400 — intervention group
Group type: EXPERIMENTAL
Intervention: ERF-free patients (n = 1051)
Number of subjects: 1417
Study 34695400 — intervention group
Group type: COMPARATOR
Intervention: ERF patients (n = 366)
Number of subjects: 1417
Study 34271853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride 0.1 mg/kg (H1)
Number of subjects: 222
Study 34271853 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride 0.2 mg/kg (H2)
Number of subjects: 222
Study 34271853 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 1.5 µg/kg (S)
Number of subjects: 222
Study 35984658 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance endoscopy between 9 and 15 months after index endoscopy
Number of subjects: 4523
Study 35984658 — intervention group
Group type: COMPARATOR
Intervention: Index endoscopy using white light and narrow-band imaging
Number of subjects: 4523
Study 35984658 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance endoscopy for patients with early GC detected during index endoscopy
Number of subjects: 4523
Study 35984658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of risk factors
Number of subjects: 4523
Study 34459239 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden carriers
Number of subjects: 17623
Study 35296141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 65
Study 35296141 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 65
Study 35296141 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 65
Study 35296141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 33099662 — intervention group
Group type: EXPERIMENTAL
Intervention: Siderophore-producing microorganisms (SPMs) including Sinorhizobium meliloti, Pseudomonas fluorescence, and P. indica
Number of subjects: 3
Study 33099662 — intervention group
Group type: EXPERIMENTAL
Intervention: P. fluorescens and P. indica (alone or in combination)
Number of subjects: 3
Study 33099662 — intervention group
Group type: EXPERIMENTAL
Intervention: Siderophore-producing microorganisms (SPMs)
Number of subjects: 3
Study 33099662 — intervention group
Group type: EXPERIMENTAL
Intervention: P. indica (alone or in combination with SPB)
Number of subjects: 3
Study 32729888 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg every 4 weeks (arm A)
Number of subjects: 263
Study 32729888 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab, 1.5 mg every 4 weeks (arm B)
Number of subjects: 263
Study 32729888 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab, 6.0 mg every 4 weeks (arm C)
Number of subjects: 263
Study 32729888 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D)
Number of subjects: 263
Study 32729888 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E)
Number of subjects: 263
Study 36063545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study 36063545 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0
Study 33725857 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Liangxue Shengji prescription (YLS)
Number of subjects: 140
Study 33725857 — intervention group
Group type: EXPERIMENTAL
Intervention: YLS
Number of subjects: 140
Study 33725857 — intervention group
Group type: COMPARATOR
Intervention: YLS placebo
Number of subjects: 140
Study 32080013 — intervention group
Group type: EXPERIMENTAL
Intervention: AttraX® Putty
Number of subjects: 100
Study 32080013 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 100
Study 32080013 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 100
Study 33471115 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for quantifying percent global glomerulosclerosis
Number of subjects: 83
Study 33471115 — intervention group
Group type: COMPARATOR
Intervention: On-call pathologists' estimates of percent global glomerulosclerosis
Number of subjects: 83
Study 33471115 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model with pooled glomeruli counts from multiple levels
Number of subjects: 83
Study 33471115 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 83
Study 34587719 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy (oral, total daily doses of 100-400 mg, later switched to 100 mg twice daily)
Number of subjects: 762